Literature DB >> 6282508

Immunological profile of amyotrophic lateral sclerosis patients and their cell-mediated immune responses to viral and CNS antigens.

H Bartfeld, C Dham, H Donnenfeld, L Jashnani, R Carp, R Kascsak, J Vilcek, M Rapport, S Wallenstein.   

Abstract

The 'immunological profile' of amyotrophic lateral sclerosis (ALS) patients was established from standard tests for B- and T-cell function. This showed no significant difference from age and sex-matched other neurological (CNS) disease controls and normal subjects. Immune complex (IC) levels in ALS serum differed significantly from normal controls but not from CNS controls. There was no relation between the various indices of immune activity of IC levels and the clinical disability of the ALS patient or progression of the disease. Distribution of complement-fixing antibodies to poliovirus was similar to sera of ALS and control groups. The in vitro cell-mediated immune responses to poliovirus, however, were significantly greater in ALS patients than in CNS controls and were inversely related to the ALS disability score. Poliovirus has not been demonstrated in the CNS or extra-CNS tissues of ALS patients by conventional means but, if latent or defective poliovirus or related virus were present, this could account for sensitization and a possible autoimmune mechanism. ALS patients exhibited in vitro cellular immunity to ALS and normal CNS subfractions. These responses were not related to the ALS disability score or progression of the disease and probably represent epiphenomena.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282508      PMCID: PMC1536567     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Preparation of synaptosomes and vesicles with sodium diatrizoate.

Authors:  H Tamir; M M Rapport; L Roizin; Y L Huang; J C Liu
Journal:  J Neurochem       Date:  1974-11       Impact factor: 5.372

2.  Neutralizing antibodies to poliovirus and mumps virus in amyotrophic lateral sclerosis.

Authors:  J R Lehrich; J Oger; B G Arnason
Journal:  J Neurol Sci       Date:  1974-12       Impact factor: 3.181

3.  Cultures of tissues from patients with amyotrophic lateral sclerosis.

Authors:  N E Cremer; L S Oshiro; F H Norris; E H Lennette
Journal:  Arch Neurol       Date:  1973-11

4.  The administration of guanidine in amyotrophic lateral sclerosis.

Authors:  F H Norris; P R Calanchini; R J Fallat; S Panchari; B Jewett
Journal:  Neurology       Date:  1974-08       Impact factor: 9.910

5.  Late progression of poliomyelitis or forme fruste amyotrophic lateral sclerosis?

Authors:  D W Mulder; R A Rosenbaum; D D Layton
Journal:  Mayo Clin Proc       Date:  1972-10       Impact factor: 7.616

6.  Soluble antigen-antibody complexes and platelet aggregation.

Authors:  K Penttinen; G Myllylä; O Mäkelä; A Vaheri
Journal:  Acta Pathol Microbiol Scand       Date:  1969

7.  Motor neurone disease: an immunological study.

Authors:  B F Tavolato; A C Licandro; A Saia
Journal:  Eur Neurol       Date:  1975       Impact factor: 1.710

8.  Amyotrophic lateral sclerosis and parkinsonism-dementia on Guam, 1945-1972. I. Descriptive epidemiology.

Authors:  D M Reed; J A Brody
Journal:  Am J Epidemiol       Date:  1975-04       Impact factor: 4.897

9.  Circulating immune complexes in multiple sclerosis and other neurological diseases.

Authors:  T G Tachovsky; R P Lisak; H Koprowski; A N Theofilopoulos; F J Dixon
Journal:  Lancet       Date:  1976-11-06       Impact factor: 79.321

10.  A suppression of cellular immunity in patients with multiple sclerosis.

Authors:  V Utermohlen; J B Zabriskie
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Immunology of amyotrophic lateral sclerosis.

Authors:  N R Cashman; M E Gurney; J P Antel
Journal:  Springer Semin Immunopathol       Date:  1985

Review 2.  Motor neuron disease: etiology, pathogenesis and treatment--a review.

Authors:  D J Donohoe; B Brady
Journal:  Ir J Med Sci       Date:  1996 Jul-Sep       Impact factor: 1.568

Review 3.  Poliovirus and motor neuron disease.

Authors:  C N Martyn
Journal:  J Neurol       Date:  1990-10       Impact factor: 4.849

4.  A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis.

Authors:  A Stevens; M Weller; H Wiethölter
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

5.  The environment in childhood and risk of motor neuron disease.

Authors:  C N Martyn; C Osmond
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

6.  Humoral factors in ALS patients during disease progression.

Authors:  Jared Ehrhart; Adam J Smith; Nicole Kuzmin-Nichols; Theresa A Zesiewicz; Israt Jahan; R Douglas Shytle; Seol-Hee Kim; Cyndy D Sanberg; Tuan H Vu; Clifton L Gooch; Paul R Sanberg; Svitlana Garbuzova-Davis
Journal:  J Neuroinflammation       Date:  2015-06-28       Impact factor: 8.322

7.  Evaluation of Peripheral Immune Activation in Amyotrophic Lateral Sclerosis.

Authors:  Mengli Wang; Zhen Liu; Juan Du; Yanchun Yuan; Bin Jiao; Xuewei Zhang; Xuan Hou; Lu Shen; Jifeng Guo; Hong Jiang; Kun Xia; Jianguang Tang; Ruxu Zhang; Beisha Tang; Junling Wang
Journal:  Front Neurol       Date:  2021-06-24       Impact factor: 4.003

8.  Humoral immune activation in amyotrophic lateral sclerosis patients.

Authors:  Michael Rentzos; Maria Eleftheria Evangelopoulos; Eleni Sereti; Vassiliki Zouvelou; Styliani Marmara; Theodoros Alexakis; Ioannis Evdokimidis
Journal:  Neurol Int       Date:  2013-02-11

9.  Melittin ameliorates the inflammation of organs in an amyotrophic lateral sclerosis animal model.

Authors:  Sun-Hwa Lee; Sun-Mi Choi; Eun Jin Yang
Journal:  Exp Neurobiol       Date:  2014-03-27       Impact factor: 3.261

Review 10.  Novel molecular biomarkers at the blood-brain barrier in ALS.

Authors:  Danijela Bataveljic; Milena Milosevic; Lidija Radenovic; Pavle Andjus
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.